M
Momelotinib
Subsidy Information and Financing Scheme
Medical Assistance Fund
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Availability of ACE Drug Guidance
Yes
Post-marketing information
Biologics Drug Information Overview
No
Active ingredient: Momelotinib
General information
Subsidy Information and Financing Scheme
[MAF] Momelotinib Tablet 100 mg, 150 mg, 200 mg
For the treatment of disease-related splenomegaly or symptoms in patients with moderate to severe anaemia who have intermediate- or high-risk myelofibrosis (MF), including primary MF, post-polycythaemia vera MF, or post-essential thrombocythaemia MF, and who are Janus Kinase inhibitor (JAKi)-naive or JAKi-experienced.
[MSHL] Momelotinib Tablets 100 mg, 150 mg, 200 mg
For the treatment of disease-related splenomegaly or symptoms in patients with moderate to severe anaemia who have intermediate- or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis, and who are Janus Kinase inhibitor (JAKi)-naive or JAKi-experienced.
Drug Guidance for Subsidy
06/02/2026 Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia
The Ministry of Health’s Drug Advisory Committee has recommended:
Momelotinib 100 mg, 150 mg and 200 mg tablets for treating myelofibrosis-related splenomegaly or symptoms in patients with moderate to severe anaemia.
Funding status
[R] Momelotinib 100 mg, 150 mg and 200 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.
Clinical indication, subsidy class and MediShield Life claim limit for momelotinib are provided in the Annex.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Tablet 100 mg |
|
Tablet 150 mg |
|
Tablet 200 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.